Everett Harris & Co. CA Sells 503 Shares of GSK plc (NYSE:GSK)

Everett Harris & Co. CA lessened its position in shares of GSK plc (NYSE:GSK) by 4.9% in the fourth quarter, according to its most recent filing with the SEC. The firm owned 9,668 shares of the pharmaceutical company’s stock after selling 503 shares during the quarter. Everett Harris & Co. CA’s holdings in GSK were worth $358,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in GSK. Fairfield Bush & CO. bought a new position in GSK during the 1st quarter valued at $80,000. JPMorgan Chase & Co. grew its holdings in shares of GSK by 2.3% during the first quarter. JPMorgan Chase & Co. now owns 241,367 shares of the pharmaceutical company’s stock worth $10,514,000 after purchasing an additional 5,518 shares in the last quarter. Panagora Asset Management Inc. bought a new stake in GSK in the 1st quarter worth approximately $467,000. Blair William & Co. IL lifted its position in GSK by 3.0% in the 1st quarter. Blair William & Co. IL now owns 37,192 shares of the pharmaceutical company’s stock worth $1,620,000 after buying an additional 1,094 shares during the last quarter. Finally, Cetera Investment Advisers boosted its stake in shares of GSK by 2.4% during the first quarter. Cetera Investment Advisers now owns 62,991 shares of the pharmaceutical company’s stock valued at $2,744,000 after purchasing an additional 1,453 shares during the period. Institutional investors and hedge funds own 15.74% of the company’s stock.

GSK Stock Down 0.3 %

Shares of NYSE GSK traded down $0.13 during mid-day trading on Thursday, reaching $42.86. 1,854,652 shares of the company were exchanged, compared to its average volume of 3,572,673. The company has a quick ratio of 0.62, a current ratio of 0.88 and a debt-to-equity ratio of 1.19. The stock has a market cap of $88.22 billion, a price-to-earnings ratio of 14.27, a P/E/G ratio of 1.94 and a beta of 0.64. GSK plc has a 1 year low of $33.33 and a 1 year high of $43.84. The firm has a 50-day moving average of $41.62 and a 200 day moving average of $38.35.

GSK (NYSE:GSK) last announced its earnings results on Wednesday, January 31st. The pharmaceutical company reported $0.72 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.76 by ($0.04). GSK had a net margin of 16.24% and a return on equity of 51.45%. The business had revenue of $10 billion for the quarter, compared to analyst estimates of $9.79 billion. On average, research analysts expect that GSK plc will post 4.07 earnings per share for the current year.

GSK Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, April 11th. Stockholders of record on Friday, February 23rd will be issued a $0.3564 dividend. The ex-dividend date is Thursday, February 22nd. This is a positive change from GSK’s previous quarterly dividend of $0.34. This represents a $1.43 dividend on an annualized basis and a dividend yield of 3.33%. GSK’s dividend payout ratio is currently 52.82%.

Analyst Upgrades and Downgrades

A number of equities analysts have issued reports on GSK shares. Jefferies Financial Group upgraded GSK from a “hold” rating to a “buy” rating in a report on Wednesday, January 3rd. Guggenheim raised GSK from a “neutral” rating to a “buy” rating in a research report on Monday, March 4th. Morgan Stanley initiated coverage on GSK in a research report on Tuesday, January 23rd. They set an “equal weight” rating on the stock. Finally, Citigroup raised GSK from a “neutral” rating to a “buy” rating in a report on Tuesday, February 13th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating, three have assigned a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, GSK has an average rating of “Moderate Buy”.

GSK Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.